Gilead Sciences | GILD - Stammkapital

Aktienkurs
138.26
Täglich Wechseln
-1.87 -1.33%
Monatlich
-5.71%
Jährlich
33.99%
Q2 Prognose
135.50




Stammkapital Veränderung Datum
AbbVie USD 1.77B 1.75B 2025-06
Agios Pharmaceuticals USD 58.45M 169K 2025-12
ALKERMES USD 165.61M 503K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amgen USD 539M 1000K 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 946.83M 354.23M 2025-06
Gilead Sciences USD 1.24B 1000K 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Glaxosmithkline GBP 4.08B 49.43M 2025-12
Incyte USD 198.46M 2.33M 2025-12
J&J USD 2.41B 584K 2025-09
Merck USD 2.49B 15.79M 2025-09
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.91B 10.64M 2025-12
Pfizer USD 5.69B 1000K 2025-09
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Sarepta Therapeutics USD 104.96M 196K 2025-12
United Therapeutics USD 43.64M 740K 2025-12
Vertex Pharmaceuticals USD 254M 0 2025-12